ArticleThoracic cancer2024

Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study.

Ayumu Otsuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.